Choosing the right option for renal-cell carcinoma
Mené sur 49 patients atteints d'un cancer à cellules rénales de stade avancé, cet essai de phase II évalue le regorafenib, du point de vue du pourcentage de patients pour lesquels une réponse objective globale a été observée
Drugs that target VEGF or pathways involving mTOR have improved progression-free survival and overall survival of patients with advanced renal-cell carcinoma1 with several VEGF receptor tyrosine-kinase inhibitors—including multikinase inhibitors—approved for use on the basis of randomised controlled trials.2 Although such drugs can improve long-term survival, most patients who take them have only temporary disease stabilisation or modest responses and need chronic treatment, increasing exposure to toxic effects associated with these drugs.3 Furthermore, drug resistance develops through bypassing of targeted pathways—a major challenge in the management of advanced renal-cell carcinoma...
The Lancet Oncology , commentaire en libre accès, 2011